| Schedule of management’s assessment for two operating segments |
Based
on management’s assessment, the Company has determined that it has two operating segments as follows:
| |
1) |
Telemedicine
and other services |
| |
2) |
Sale
of medicine and medical devices |
Schedule of management’s assessment for two operating segments
| | |
| 2025 | | |
| 2024 | | |
| 2023 | |
| | |
As of June 30, | |
| | |
| 2025 | | |
| 2024 | | |
| 2023 | |
| | |
| US$ | | |
| US$ | | |
| US$ | |
| | |
| | | |
| | | |
| | |
| Telemedicine and other services | |
| 6,800,287 | | |
| 12,857,688 | | |
| 6,898,166 | |
| Sale of medicine and medical devices | |
| 846,452 | | |
| 1,110,847 | | |
| 976,720 | |
| Total revenue | |
| 7,646,739 | | |
| 13,968,535 | | |
| 7,874,886 | |
| | |
| | | |
| | | |
| | |
| Telemedicine and other services | |
| 5,630,553 | | |
| 10,487,767 | | |
| 5,948,232 | |
| Sale of medicine and medical services | |
| 736,068 | | |
| 942,395 | | |
| 831,660 | |
| Total cost of revenue | |
| 6,366,621 | | |
| 11,430,162 | | |
| 6,779,892 | |
|
| Schedule of present summary information by segment |
The
following tables present summary information by segment for the years ended June 30, 2025, 2024 and 2023, respectively:
Schedule
of present summary information by segment
| | |
| | |
| | |
| |
| | |
Years Ended June 30, 2025 | |
| | |
Telemedicine and other services | | |
Sale of medicine and medical devices | | |
Consolidated totals | |
| | |
US$ | | |
US$ | | |
US$ | |
| | |
| | |
| | |
| |
| Revenue | |
| 6,800,287 | | |
| 846,452 | | |
| 7,646,739 | |
| Gross profit | |
| 1,169,734 | | |
| 110,384 | | |
| 1,280,118 | |
| Loss before income tax expense | |
| (3,132,486 | ) | |
| (251,320 | ) | |
| (3,383,806 | ) |
| Net loss | |
| (3,132,486 | ) | |
| (251,320 | ) | |
| (3,383,806 | ) |
| | |
| | | |
| | | |
| | |
| Total reportable assets | |
| 4,104,014 | | |
| 343,936 | | |
| 4,447,950 | |
| 12 |
Segment Reporting (continued) |
| | |
| | |
| | |
| |
| | |
Years Ended June 30, 2024 | |
| | |
Telemedicine and other services | | |
Sale of medicine and medical devices | | |
Consolidated totals | |
| | |
US$ | | |
US$ | | |
US$ | |
| | |
| | |
| | |
| |
| Revenue | |
| 12,857,688 | | |
| 1,110,847 | | |
| 13,968,535 | |
| Gross profit | |
| 2,369,921 | | |
| 168,452 | | |
| 2,538,373 | |
| Loss before income tax expense | |
| (15,357,637 | ) | |
| (264,349 | ) | |
| (15,621,986 | ) |
| Net loss | |
| (15,338,443 | ) | |
| (264,349 | ) | |
| (15,602,792 | ) |
| | |
| | | |
| | | |
| | |
| Total reportable assets | |
| 7,328,740 | | |
| 621,875 | | |
| 7,950,615 | |
| | |
| | |
| | |
| |
| | |
Years Ended June 30, 2023 | |
| | |
Telemedicine services | | |
Sale of medicine and medical devices | | |
Consolidated totals | |
| | |
US$ | | |
US$ | | |
US$ | |
| | |
| | |
| | |
| |
| Revenue | |
| 6,898,166 | | |
| 976,720 | | |
| 7,874,886 | |
| Gross profit | |
| 949,934 | | |
| 145,060 | | |
| 1,094,994 | |
| Loss before income tax expense | |
| (2,965,165 | ) | |
| (248,195 | ) | |
| (3,213,360 | ) |
| Net loss | |
| (2,965,165 | ) | |
| (248,195 | ) | |
| (3,213,360 | ) |
| | |
| | | |
| | | |
| | |
| Total reportable assets | |
| 3,121,643 | | |
| 320,896 | | |
| 3,442,539 | |
|